Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

21 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

TNM Staging GSK study Prostatic neoplasms NCT00883909

- 26.11.17 - 1 Formular, 2 Itemgruppen, 6 Datenelemente, 1 Sprache
Itemgruppen: Administrative data, TNM Staging History
Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate CRF Seiten: 934-977

Staging NSCLC (UICC and AJCC), University Hospital Cologne

- 31.03.17 - 1 Formular, 2 Itemgruppen, 4 Datenelemente, 1 Sprache
Itemgruppen: Staging of NSCLC - UICC, Staging NSCLC - AJCC
Hospital Routine Documentation Subform at the University Hospital Cologne Original Form name: CIO STADIENEINTEILUNG NSCLC.pdf

Tumor Documentation University Hospital Cologne

- 13.03.17 - 1 Formular, 11 Itemgruppen, 69 Datenelemente, 1 Sprache
Itemgruppen: Tumor Documentation, Status at Initial Diagnosis, Location, Recurrent Tumor, Pathology, Lymph nodes, Procedere, Operative Surgical Procedures, Therapeutic Radiology, Chemotherapy, Case Management, Palliative medicine, oncologic psychotherapy
Study Description: Hospital Routine Documentation Subform at the University Hospital Cologne. Original Form name: Tumordokumentation CIO

Restaging NHL PETAL Study NCT00554164 - Restaging

- 23.11.16 - 1 Formular, 8 Itemgruppen, 57 Datenelemente, 2 Sprachen
Itemgruppen: General health, Time of follow-up, Staging, Lab results, Nodal involvement, Extranodal involvement, Overall result, Footer module
Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

Restaging PETAL Study NCT00554164 - Restaging

- 22.11.16 - 1 Formular, 9 Itemgruppen, 63 Datenelemente, 2 Sprachen
Itemgruppen: Patient demographics, Staging, Lab results, Nodal involvement, Extranodal involvement, Overall result, Dscontinuation of therapy, IPI, Footer module
Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

Staging PETAL Study NCT00554164 - Staging

- 18.11.16 - 1 Formular, 9 Itemgruppen, 60 Datenelemente, 2 Sprachen
Itemgruppen: Patient demographics, Therapy, Staging, Lab results, Nodal involvement, Extranodal involvement, Overall result, IPI, Footer module
Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

EBMT Multiple Myeloma General Information - 16pp EBMT Multiple Myeloma 10PCD

- 29.06.16 - 1 Formular, 18 Itemgruppen, 283 Datenelemente, 1 Sprache
Itemgruppen: EBMT FORM GENERAL INFORMATION, PATIENT, DISEASE, PLASMA CELL DISORDERS (INCLUDING MULTIPLE MYELOMA), PRE-HSCT TREATMENT, HSCT, STATUS OF DISEASE AT COLLECTION, DISEASE STATUS AT HSCT, ADDITIONAL TREATMENT POST-HSCT, STATUS OF DISEASE AT 100 DAYS AFTER HSCT, FORMS TO BE FILLED IN, PLASMA CELL DISORDERS (INCLUDING MULTIPLE MYELOMA), PATIENT LAST SEEN, GRAFT VERSUS HOST DISEASE (GvHD) SINCE LAST REPORT, OTHER COMPLICATIONS SINCE LAST REPORT, ADDITIONAL THERAPIES SINCE LAST FOLLOW UP, FIRST EVIDENCE OF RELAPSE OR PROGRESSION SINCE LAST HSCT, LAST DISEASE AND PATIENT STATUS
DOCUMENTED PATHOGENS (Use this table for guidance on the pathogens of interest) Bacteria:S. pneumoniae,OHaemophilus influenzaether gram positive (i.e.: other streptococci, staphylococci, listeria …), Other gram negative (i.e.: E. coli klebsiella, proteus, serratia, pseudomonas …), Legionella sp,Mycobacteria sp, Other Fungi:Candida sp, Aspergillus sp, Pneumocystis carinii, Other Parasites: Toxoplasma gondii, Other Viruses: HSV, VZV, EBV,CMV,HHV-6, RSV,Other respiratory virus (influenza, parainfluenza, rhinovirus),Adenovirus, HBV, HCV, HIV,Papovavirus, Parvovirus, Other

General Info EBMT Lymphoma - 16pp General Info EBMT Lymphoma 04 Lym.

- 31.05.16 - 1 Formular, 17 Itemgruppen, 224 Datenelemente, 1 Sprache
Itemgruppen: GENERAL INFORMATION, GENERAL INFORMATION, DISEASE, LYMPHOMA, TREATMENT GIVEN BEFORE THE 1ST TRANSPLANT, DISEASE HISTORY BEFORE HSCT, STATUS OF DISEASE AT HSCT, ADDITIONAL TREATMENT POST-HSCT, BEST DISEASE RESPONSE AT 100 DAYS POST-HSCT, FORMS TO BE FILLED IN, LYMPHOMA FOLLOW UP, GRAFT VERSUS HOST DISEASE (GvHD) SINCE LAST REPORT, OTHER COMPLICATIONS SINCE LAST REPORT, DATE(S) AND RESULTS OF ALL TESTS DONE FOR ALL DONORS, ADDITIONAL THERAPIES SINCE LAST FOLLOW UP, FIRST EVIDENCE OF RELAPSE OR PROGRESSION SINCE LAST HSCT, ADDITIONAL NOTES IF APPLICABLE
DOCUMENTED PATHOGENS (Use this table for guidance on the pathogens of interest) Bacteria: S. pneumoniae, Other gram positive (i.e.: other streptococci, staphylococci, listeria …), Haemophilus influenzae, Other gram negative (i.e.: E. coli klebsiella, proteus, serratia, pseudomonas …), Legionella sp, Mycobacteria sp, Other Fungi:Candida sp, Aspergillus sp, Pneumocystis carinii, Other Parasites: Toxoplasma gondii, Other Viruses: HSV, VZV, EBV, CMV, HHV-6, RSV, Other respiratory virus (influenza, parainfluenza,rhinovirus), Adenovirus, HBV, HCV, HIV, Papovavirus, Parvovirus, Other

Staging after Consolidation LenaMain-Study - Staging after Consolidation

- 17.03.16 - 1 Formular, 8 Itemgruppen, 75 Datenelemente, 1 Sprache
Itemgruppen: Monthly control visit with response evaluation, Parameter of multiple myeloma, Vital signs, Laboratory:Protein electrophoresis, Laboratory:Hematology, Laboratory:serum chemistry, Laboratory:pregnancy test, Quality of life
A randomised comparison of daily 25 mg versus 5 mg lenalidomide as maintenance therapy after high-dose therapy and autologous stem cell transplantation in patients with multiple myeloma. Protocol-Code: RV-MM-PI-280 EudraCT-Number: 2007-003945-33 Author: Claus Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr. med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann, Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-Studie: Prof. Roland Fenk, Düsseldorf Coordinating center for clinical trial Medical faculty of University Hospital Heinrich-Heine-University Scientific Director: Herr Dr. J. Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0) 211-81-19701 Fax: +49 (0) 211-81-19702

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video